All In Biotech

Drug Trial Radar · NCT03818321

Urinary Track Infection Prevention After Urogynecological Surgery

Methenamine Hippurate With Cranberry Capsules Versus Cranberry Capsules Alone for UTI Prevention in a Short-term Indwelling Foley Catheter Population After Urogynecological Surgery: A Double-Blinded Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

185

Actual

Start

Jun 17, 2019

Primary completion

Jul 1, 2021

Study completion Jul 1, 2021

Sponsor

Lead sponsor
TriHealth Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is randomized double-blinded placebo-controlled trial to access oral Methenamine Hippurate (MH) in combination with cranberry capsules is superior to cranberry capsules alone in prevention of UTI in patients with transient post-operative urinary retention requiring a Foley catheter after pelvic reconstructive surgery.

Conditions

  • Urinary Tract Infections
  • Urinary Retention Postoperative
  • Pelvic Organ Prolapse

Interventions

  • Methenamine Hippurate 1 g tabletDrug

    Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).

  • Placebo tabletDrug

    Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Urinary Track Infection (UTI)Time frame: From surgery to one week post-op visit, approximately 1 week post surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cincinnati Urogynecology Associates

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.